Researchers found an effective and acceptable intervention for patients with relapsed/refractory multiple myeloma (MM). The findings were published in JMIR Formative Research.
“Recent studies have found that electronic patient-reported outcome (ePRO) interventions implemented in the clinic setting have had positive outcomes for other oncology populations. Evidence of the efficacy of a similar approach is lacking for patients with relapsed/refractory MM,” the researchers wrote.
In this study, researchers enlisted 11 patients (nine completed the study) with relapsed/refractory MM to report on 17 symptoms during four sessions using a mobile app. The sessions took place one week apart. The researchers noted that when reports met predefined thresholds, patients received automated guidance. Study endpoints were assessed using qualitative and quantitative methods. Overall, 83% of the weekly sessions were completed.
According to the findings, patients found the frequency and time required to complete reporting acceptable. Moreover, they all agreed that the app was easy to use and understand. Encouragingly, both patients and providers agreed it would be beneficial for patients to report for longer than four weeks. Although patients felt that the training they received was adequate, they felt it contained too much information to digest in one session. Furthermore, while neither patients nor providers viewed the in-app data reports, they agreed on their potential value.
“Overall, the intervention was found to be acceptable and appropriate for patients with relapsed/refractory MM,” the researchers concluded. “This study underlines the importance of an iterative approach to implementation that includes all stakeholders in order to ensure successful adoption.”